The disease control rate was 92%, and the median progression-free survival was 13.7 months. Treatment with 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and pembrolizumab appeared well ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — ...

Pre-operative fractionated stereotactic radiotherapy (FSRT) may produce better outcomes than post-operative FSRT in cancer patients with brain metastases.

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

Patients with recurrent glioblastoma may derive a greater benefit from sacituzumab govitecan if they have high TROP2 expression.

In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients ...

A CXB boost continues to provide an organ preservation benefit at 5 years, though there is some local regrowth after 3 years, ...

More research is needed to investigate the cause of the decline in cutaneous melanoma incidence among young patients, researchers say.

Critics say that, if RFK Jr. is made secretary of the HHS, a radical antiestablishment medical movement with roots in past centuries would take power.

(HealthDay News) — President-elect Donald Trump says he will nominate Mehmet Oz, MD, to head the Centers for Medicare & Medicaid Services. In a statement, Trump said that Oz will “work closely with ...

Interventions to improve health literacy should be further investigated or developed to assist individuals with limited ...